Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05505734 · ClinicalTrials.gov registry record · Phase 3
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
A Phase 3 study of Asthma, sponsored by Bond Avillion 2 Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,516
- Enrollment target
- 20
- Study locations
NCT05505734: Completed Phase 3 study of Asthma, sponsored by Bond Avillion 2 Development.
NCT05505734 is a Phase 3 study of Asthma that has completed, run by Bond Avillion 2 Development. The registered enrollment target is 2,516 participants, above the 1,557-participant average among 374 other Asthma trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05505734, a Phase 3 study of Asthma, has completed, sponsored by Bond Avillion 2 Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,516 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a US study comparing the efficacy and safety of BDA MDI \[Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)\] with AS \[Albuterol Sulfate\] MDI, both are administered as needed for up to 12 months.
Primary Outcome
The time to first severe asthma exacerbation was analyzed under the While on Treatment strategy in the Full analysis set (FAS) and was defined as the length in days from treatment initiation until the date of the first severe asthma exacerbation event. Participants were censored at treatment discontinuation, a step-up in maintenance therapy, or interim analysis DCO. An asthma exacerbation was considered severe if it resulted in at least one of the following: use of systemic steroids for at least
Conditions Studied
Interventions
- DRUG BDA MDI
- DRUG AS MDI
Study Locations (20)
Georgia
- Centricity Research - Columbus
- Centricity Research - Columbus
- Centricity Research - Columbus
- Centricity Research - Columbus
- Lifeline Primary Care - Lilburn
- Javara Inc./Privia Medical Group Georgia, LLC - Savannah
California
- Kern Research Inc. - Bakersfield
- Science 37 - Culver City
- Antelope Valley Clinical Trials - Lancaster
- Allergy & Asthma Medical Group and Research (AAMGRC) - Allergy, Asthma and Immunology - San Diego
- Clinical Research of California - Walnut Creek
Arizona
- One of a Kind Clinical Research Center - Paradise Valley
- Fiel Family and Sports Medicine/CCT Research - Tempe
Colorado
- Asthma and Allergy Associates - Colorado Springs
- Velocity Clinical Research, Denver - Denver
Florida
- Helix Biomedics - Boynton Beach
- Allergy and Asthma Diagnostic Treatment Center - Tallahassee
Alabama
- Pulmonary Associates of Mobile PC - Mobile
Idaho
- Velocity Clinical Research - Boise - Meridian
Indiana
- Velocity Clinical Research - Valparaiso - Valparaiso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,516 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 3 |
What the finished NCT05505734 record still lists
NCT05505734 is an interventional study that assigns participants to a tested intervention. Its 2,516 participants enrollment target places it among the larger protocols in the corpus, above the 1,557-participant average among 374 other Asthma trials with a reported enrollment target (62% higher).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which BDA MDI is the first listed.
NCT05505734 names 20 study sites across 8 states, led by Georgia, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05505734 about?
NCT05505734 is a clinical study titled "A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma". This is a US study comparing the efficacy and safety of BDA MDI \[Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)\] with AS \[Albuterol Sulfate\] MDI, both are administered as needed for up to 12 months.
What is the current status of trial NCT05505734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,516 participants. The study started on 2022-09-02. Estimated completion is 2024-08-22.
What conditions does trial NCT05505734 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05505734?
The interventions under investigation include: BDA MDI (DRUG), AS MDI (DRUG).
Who is sponsoring clinical trial NCT05505734?
This trial is sponsored by Bond Avillion 2 Development, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05505734 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05505734's enrollment target sits among peer trials
2,516 21st of 374 higher than 354 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI